Lenzilumab KB 003|cas:1229575-09-0|西域试剂

Lenzilumab KB 003,99.64%

产品编号：Bellancom-P99207| CAS NO：1229575-09-0

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	价格	库存与货期
Bellancom-P99207	￥2800.00	杭州北京（现货）
Bellancom-P99207	￥7000.00	杭州北京（现货）
Bellancom-P99207	￥11200.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

Lenzilumab KB 003

产品介绍

Lenzilumab (KB 003) 是一种靶向 CSF2/GM-CSF 的人源化单克隆抗体，可用于 COVID-19、慢性粒单核细胞白血病 (CMML) 和幼年粒单核细胞白血病 (JMML) 研究。

生物活性

Lenzilumab (KB 003) is a humanized monoclonal antibody targeting CSF2/GM-CSF for COVID-19, chronic myelomonocytic leukemia (CMML) and juvenile myelomonocytic leukemia (JMML) studies.

体外研究

体内研究

Lenzilumab (i.p., 10 mg/kg, daily, 10 days) inhibits GM-CSF without inhibiting the cellular function of CAR-T and enhances its antitumor activity in NSG mice.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	NSG mice with CART19 cells
Dosage:	10 mg/kg
Administration:	Intraperitoneal injection; daily; 10 days
Result:	Neutralized GM-CSF, had antitumor activity and improved the proliferation of cytokine release syndrome (CRS) and neuroinflammation (NI).

体内研究

Lenzilumab (i.p., 10 mg/kg, daily, 10 days) inhibits GM-CSF without inhibiting the cellular function of CAR-T and enhances its antitumor activity in NSG mice.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	NSG mice with CART19 cells
Dosage:	10 mg/kg
Administration:	Intraperitoneal injection; daily; 10 days
Result:	Neutralized GM-CSF, had antitumor activity and improved the proliferation of cytokine release syndrome (CRS) and neuroinflammation (NI).